Cardiovascular and ocular safety of α₁-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms

Bibliography

• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the Amcerican Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014;16:14-26
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction. Eur Urol 2013;64:118-40
   PubMed Web of Science ®Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005;4:53-60
   Web of Science ®Google Scholar
• Michel MC. The forefront of novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - How do they work and why do they differ in tolerability? J Pharmacol Sci 2010;112:151-7
   PubMed Web of Science ®Google Scholar
• Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on alpha1-adrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29-36
   PubMedGoogle Scholar
• Michel MC, Mehlburger L, Bressel H-U, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol 1998;160:784-91
   PubMed Web of Science ®Google Scholar
• Bird ST, Delaney JA, Brophy JM, et al. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013;347:f6320
   PubMedGoogle Scholar
• Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8
   PubMed Web of Science ®Google Scholar
• Franco-Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral-controlled absorption system formulations. Clin Pharmacokinet 2010;49:177-88
   PubMed Web of Science ®Google Scholar
• Rouquier I, Claustre Y, Benavides J. Alpha1-Adrenoceptor antagonists differentially control serotonin release in the hippocampcus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59-64
   PubMed Web of Science ®Google Scholar
• Guo TZ, Tinklenberg J, Oliker R, et al. Central alpha1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an alpha2-adrenoceptor agonist. Anesthesiology 1991;75:252-6
   PubMed Web of Science ®Google Scholar
• van Dijk MM, Skrekas T, de la Rosette JJ. The association between lower urinary tract symptoms and sexual dysfunction: fact or fiction? Curr Opin Urol 2005;15:39-44
   PubMed Web of Science ®Google Scholar
• van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha1-adrenoceptor antagonists on male sexual function. Drugs 2006;66:287-301
   PubMed Web of Science ®Google Scholar
• Giuliano F, Oelke M, Jungwirth A, et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggstive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamulsosin-controlled, 12-week double-blind study. J Sex Med 2013;10:857-65
   PubMed Web of Science ®Google Scholar
• Homma Y, Kawabe K, Takeda M, et al. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010;76:1446-50
   PubMed Web of Science ®Google Scholar
• Rosen RC, Fitzpatrick JM. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2009;104:974-83
   PubMed Web of Science ®Google Scholar
• Narayan P, O’Leary MP, Davidai G. Early effect of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res 2005;5:237-45
   Google Scholar
• Buzelin JM, Fonteyne E, Kontturi MJ, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597-605
   PubMedGoogle Scholar
• Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006-12
   PubMed Web of Science ®Google Scholar
• Wu YJ, Dong Q, Liu LR, et al. A meta-analysis of efficacy and safety of the new alpha1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Prostate Cancer Prost Dis 2013;16:78-83
   Web of Science ®Google Scholar
• Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trials performed in Europe. Eur Urol 2011;59:342-52
   PubMed Web of Science ®Google Scholar
• Sanbe A, Tanaka Y, Fujiwara Y, et al. Alpha1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol 2007;152:332-40
   PubMed Web of Science ®Google Scholar
• Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994;44:46-51
   PubMed Web of Science ®Google Scholar
• Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49:295-320
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Plosker GL. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. Drugs 2005;65:2037-47
   PubMed Web of Science ®Google Scholar
• Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-56
   PubMed Web of Science ®Google Scholar
• Brodde O-E, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-89
   PubMed Web of Science ®Google Scholar
• Lee SH, Park KK, Mah SY, et al. Effects of alpha-blocker ’add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer Prost Dis 2010;13:333-7
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59
   PubMed Web of Science ®Google Scholar
• Lukacs B, Blondin P, MacCarthy C, et al. Safety profile of 3 months’ therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996;29:29-35
   PubMed Web of Science ®Google Scholar
• Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl 2005;4:9-14
   Web of Science ®Google Scholar
• Barendrecht MM, Koopmans RP, de la Rosette JJ, et al. Treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005;95(Suppl 4):19-28
   PubMedGoogle Scholar
• Lukacs B, Grange JC, Comet D, et al. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 2000;37:183-90
   PubMed Web of Science ®Google Scholar
• Lukacs B, Leplege A, Thibault P, et al. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731-40
   PubMed Web of Science ®Google Scholar
• Michel MC, Bressel H-U, Goepel M, et al. A 6-months large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001;51:609-14
   PubMed Web of Science ®Google Scholar
• Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997;19:730-42
   PubMed Web of Science ®Google Scholar
• Singh DV, Mete UK, Mandal AK, et al. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 2014;11:187-96
   PubMed Web of Science ®Google Scholar
• Troost J, Tatami S, Tsuda Y, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 2011;72:247-56
   PubMed Web of Science ®Google Scholar
• Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73
   PubMed Web of Science ®Google Scholar
• Chang DF, Osher RH, Wang L, et al. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology 2007;114:957-64
   PubMed Web of Science ®Google Scholar
• Chadha V, Borooah S, Tey A, et al. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalmol 2007;91:40-2
   PubMed Web of Science ®Google Scholar
• Issa SA, Hadid OH, Baylis O, et al. Alpha antagonists and intraoperative floppy iris syndrom: a spectrum. Clin Ophthalmol 2008;2:735-41
   PubMedGoogle Scholar
• Nguyen DQ, Sebastian RT, Kyle G. Surgeon’s experiences of the intraoperative floppy iris syndrome in the United Kingdom. Eye(Lond) 2007;21:443-4
   Google Scholar
• Blouin MC, Blouin J, Perreault S, et al. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors. Comparison of tamsulosin and alfuzosin. J Cataract Refract Surg 2007;33:1227-34
   PubMed Web of Science ®Google Scholar
• Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floopy-iris syndrom. J Cataract Refract Surg 2006;32:1336-9
   PubMed Web of Science ®Google Scholar
• Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floopy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist. Am J Ophthalmol 2007;143:150-1
   PubMed Web of Science ®Google Scholar
• Takmaz T, Can I. Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin. Eur J Ophthalmol 2007;17:909-13
   PubMed Web of Science ®Google Scholar
• Keklikci U, Isen K, Unlu K, et al. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. Acta Ophthalmol 2009;87:306-9
   PubMed Web of Science ®Google Scholar
• Neff KD, Sandoval HP, Fernandez de Castro LE, et al. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009;116:658-63
   PubMed Web of Science ®Google Scholar
• Chen AA, Kelly JP, Bhandari A, et al. Pharmacologic prophylaxis and risk factors for intraoperative floppy-iris syndrome in phacoemulsification performed by resident physicians. J Cataract Refract Surg 2010;36:898-905
   PubMed Web of Science ®Google Scholar
• Haridas A, Syrimi M, Al-Ahmar B, et al. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin - a UK-based comparison of incidence and complication rates. Graefes Arch Clin Exp Ophthalmol 2013;251:1541-5
   PubMed Web of Science ®Google Scholar
• Storr-Paulsen A, Jorgensen JS, Norregaard JC, et al. Corneal endothelial. cell changes after cataract surgery in patients on systemic sympathetic alpha1a antagonist medication (tamsulosin). Acta Ophthalmol 2014;92(4):359-63
   PubMedGoogle Scholar
• Chang DF, Campbell JR, Colin J, et al. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology 2014;121:829-34
   PubMed Web of Science ®Google Scholar
• Herd MK. Intraoperative floppy-iris syndrome with doxazosin. J Cataract Refract Surg 2010;33:562-2
   Google Scholar
• Casuccio A, Cillino G, Pavone C, et al. Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011;37:1447-54
   PubMed Web of Science ®Google Scholar
• Pärssinen O, Leppänen E, Keski-Rahkonen P, et al. Influence of tamsulosin on the iris and its implications for cataract surgery. Invest Ophthalmol Vis Sci 2006;47:3766-71
   PubMed Web of Science ®Google Scholar
• Venkatesh R, Veena K, Gupta S, et al. Intraoperative floppy iris syndrome associated with terazosin. Indian J Ophthalmol 2007;55:395-6
   PubMedGoogle Scholar
• Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 2011;118:730-5
   PubMed Web of Science ®Google Scholar
• Michel MC, Okutsu H, Noguchi Y, et al. In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn-Schmiedebergs Arch Pharmacol 2006;372:346-53
   PubMed Web of Science ®Google Scholar
• Palea S, Chang DF, Rekik M, et al. Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles. Possible model for intraoperative floppy-iris syndrome. J Cataract Refract Surg 2008;34:489-96
   PubMed Web of Science ®Google Scholar
• Goseki T, Ishikawa H, Ogasawara S, et al. Effects of tamsulosin and silodosin on isolated albino and pigmented rabbits iris dilators: possible mechanism of intraoperative floppy iris syndrome. J Cataract Refract Surg 2013;38:1643-9
   Web of Science ®Google Scholar
• Osher RH. Association between IFIS and Flomax. J Cataract Refract Surg 2006;32:547-7
   PubMed Web of Science ®Google Scholar
• Santaella RM, Destafeno JJ, Stinnett SS, et al. The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. Ophthalmology 2010;117:1743-9
   PubMed Web of Science ®Google Scholar
• Prata TS, Palmiero P-M, Angelilli A, et al. Iris morphologic changes related to alpha1-adrenergic receptor antagonists. Implications for intraoperative floppy iris syndrome. Ophthalmology 2009;116:877-81
   PubMed Web of Science ®Google Scholar
• Knowlton KU, Michel MC, Itani M, et al. The alpha1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993;268:15374-80
   PubMed Web of Science ®Google Scholar
• Altan-Yaycioglu R, Yaycioglu O, Gul U, et al. The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study. Naunyn-Schmiedeberg’s Arch Pharmacol 2007;375:199-203
   Google Scholar
• Pringle E, Packard R. Antipsychotic agent as an etiologic agent of IFIS. J Cataract Refract Surg 2005;31:2240-1
   PubMed Web of Science ®Google Scholar
• Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. Eur J Ophthalmol 2011;21:210-11
   PubMed Web of Science ®Google Scholar
• Ugarte M, Leong T, Rassam S, et al. Intraoperative floppy-iris syndrome, alpha1-adrenergic antagonists, and chronic intake of mianserin: is there an association? J Cataract Refract Surg 2007;33:170-0
   PubMed Web of Science ®Google Scholar
• Calotti F, Steen D. Labetalol causing intraoperative floppy-iris syndrome. J Cataract Refract Surg 2007;33:170-1
   PubMed Web of Science ®Google Scholar
• Chatziralli IP, Sergentanis TN, Papazisis L, et al. Risk factors for intraoperative floppy iris syndrome: a retrospective study. Acta Ophthalmol 2012;90:e152-3
   PubMed Web of Science ®Google Scholar
• Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011;37:1351-4
   PubMed Web of Science ®Google Scholar
• Issa SA, Dagres E. Intraoperative floppy-iris syndrom and finasteride intake. J Cataract Refract Surg 2007;33:2141-3
   Google Scholar
• Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg 2007;33:927-8
   PubMed Web of Science ®Google Scholar
• Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999;38:208-15
   PubMed Web of Science ®Google Scholar
• Storr-Paulsen A, Norregaard JC, Borne KK, et al. Intraoperative floppy iris syndrome (IFIS): a practical approach to medical and surgical considerations in cataract extractions. Acta Ophthalmol 2009;87:704-8
   PubMed Web of Science ®Google Scholar
• Martin-Moro JG, Negrete FM, Escobar IL, et al. Sindrome del iris flacido intraoperatorio. Arch Soc Espan Oftalmol 2013;88:64-76
   PubMedGoogle Scholar
• The Ophthalmic News & Education Network. Clinical statement on IRIS. 2014. Available from: http://one.aao.org/clinical-statement/intraoperative-floppy-iris-syndrome-ifis-associate-2 [Last accessed 4 June 2014]
   Google Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controleld clinical trial. Eur Urol 2012;61:917-25
   PubMed Web of Science ®Google Scholar